{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:16Z","timestamp":1761513676149},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.clml.2015.07.643","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T06:28:41Z","timestamp":1438928921000},"page":"699-704","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A\u00a0Single-Center Experience"],"prefix":"10.1016","volume":"15","author":[{"given":"Moussab","family":"Damlaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanna H.","family":"Sulai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.07.643_bib1","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in\u00a0vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.643_bib3","first-page":"27","article-title":"Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia","volume":"1","author":"Brito-Babapulle","year":"1987","journal-title":"Hematol Pathol"},{"key":"10.1016\/j.clml.2015.07.643_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(91)90228-M","article-title":"Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia","volume":"55","author":"Brito-Babapulle","year":"1991","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2015.07.643_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1365-2141.2000.02256.x","article-title":"T-cell prolymphocytic leukaemia: antigen receptor gene rearrangement and a novel mode of MTCP1 B1 activation","volume":"110","author":"De Schouwer","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.643_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/gcc.22141","article-title":"Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia","volume":"53","author":"Bergmann","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2015.07.643_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib8","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2015.07.643_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.643_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French Society for Stem Cell Transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.07.643_bib12","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib14","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.643_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.07.643_bib16","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.643_bib18","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2010.033159","article-title":"Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia","volume":"96","author":"Montagna","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.07.643_bib20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2015.07.643_bib21","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2010-12-319467","article-title":"FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia\/lymphoma","volume":"118","author":"Elliott","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib22","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/leu.2012.74","article-title":"Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia","volume":"26","author":"Bains","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.643_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.07.643_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Bellanger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.643_bib25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.643_bib26","unstructured":"al. EIAe. Discovery of novel drug sensitivities in t-prolymphocytic leukemia (T-PLL) by high-throughput ex\u00a0vivo drug testing and genetic profiling [abstract]. Paper presented at: ASH Meeting\u00a02014."},{"key":"10.1016\/j.clml.2015.07.643_bib27","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:38:27Z","timestamp":1599435507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015010757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S2152265015010757"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.643","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A\u00a0Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}